Breast Tissue Temperature Analysis Patent Award for Cancer Detection
RENO, Nev., Sept. 20, 2012 /PRNewswire/ -- First Warning Systems, Inc. announces the award of US Patent #8,231,542 B2 for System For Analyzing Thermal Data Based on Breast Surface Temperature to Determine Suspect Conditions.
Jim Holmes, First Warning's CEO said "This System patent completes our group of three software patents. We now have our Methods, Device and System patents which provide the Company with protection of its developed technology. Methods for Collecting and Analyzing Thermal Data Based on Breast Surface Temperature to Determine Suspect Conditions; Device For Analyzing Thermal Data Based On Breast Surface Temperature For Detection For Use In Determining Cancerous Conditions; and, System For Analyzing Thermal Data Based On Breast Surface Temperature To Determine Suspect Conditions."
First Warning Systems is currently updating the patient data collection device and its interpretive software, covered by these patents, and the Predictive Analytics modeling to complete the product package in preparation for market entry. First Warning is conducting a funding round. Company information is being posted on GUST (an association of angel investors who are accredited and qualified).
About First Warning Systems Process
Temperature readings of breast tissue create Dynamic Thermal Finger Prints (DTFP) which are correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare DTFPs to the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast cancerous cells. FWS delivers a report to the primary care physician with industry leading 90% accuracy. The FWS process is the only detection process that identifies abnormalities before a tumor presents, can be used by a primary care physician.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS' principal shareholder is Lifeline Biotechnologies, Inc. Lifeline has licensed (includes a revenue royalty feature) FWS with the worldwide exclusive right for development, manufacturing, marketing and commercialization of its intellectual property. The product is a device and process that detects breast tissue abnormalities. Many of these tissue abnormalities will develop into breast diseases, some of which will be breast cancers. The FWS process does not involve compression or radiation and is noninvasive. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russian markets. See FWS' video, "Breast Cancer Tumor Progression" at www.firstwarningsystems.com.
Safe Harbor: Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
For more information, contact: Jim Holmes, CEO 775-852-3222 Email: firstname.lastname@example.org
SOURCE First Warning Systems, Inc.